b lactamase id (Streck Laboratories)
Streck Laboratories is a verified supplier 
Streck Laboratories manufactures this product 
93
Structured Review
Streck Laboratories
b lactamase id
B Lactamase Id, supplied by Streck Laboratories, used in various techniques. Bioz Stars score: 93/100, based on 19 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/b+lactamase+id/ARM-D+Kit%2C+%C3%9F-Lactamase/pm29298125-42-54-56
Average 93 stars, based on 19 article reviews
B Lactamase Id, supplied by Streck Laboratories, used in various techniques. Bioz Stars score: 93/100, based on 19 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/b+lactamase+id/ARM-D+Kit%2C+%C3%9F-Lactamase/pm29298125-42-54-56
Average 93 stars, based on 19 article reviews
b lactamase id - by Bioz Stars,
2026-09
93/100 stars
Images
Related Articles
Polymerase Chain Reaction:Article Title: Nontyphoidal Salmonella enterica Nonsusceptible to Both Levofloxacin and Ceftriaxone in Nebraska, United States 2014-2015. Article Snippet: Nontyphoidal Salmonella enterica is a common cause of illness in humans ranging from gastroenteritis to invasive disease.. National surveillance programs continually monitor trends in antimicrobial resistance patterns and mechanisms of resistance to identify emerging public health threats.. Our study shows the emergence of nonsusceptibility to both levofloxacin and ceftriaxone, a concerning phenotype that threatens first-line antibiotic therapy, in Salmonella isolates recovered between 2014 and 2015. Plasmid Preparation:Article Title: Nontyphoidal Salmonella enterica Nonsusceptible to Both Levofloxacin and Ceftriaxone in Nebraska, United States 2014-2015. Article Snippet: Nontyphoidal Salmonella enterica is a common cause of illness in humans ranging from gastroenteritis to invasive disease.. National surveillance programs continually monitor trends in antimicrobial resistance patterns and mechanisms of resistance to identify emerging public health threats.. Our study shows the emergence of nonsusceptibility to both levofloxacin and ceftriaxone, a concerning phenotype that threatens first-line antibiotic therapy, in Salmonella isolates recovered between 2014 and 2015. |